Sequent Scientific Ltd.

Financial

	Sequent Scientific	Panacea Biotec	RPG Life Sciences
Operational Metrics
Pharmaceutical Sector
R&D as a % of Total Sales	0.0	6.74 %	2.34 %
Financials
5 yr Average ROE	3.75 %	19.34 %	16.75 %
5yr average Equity Multiplier	2.1	2.01	1.43
5yr Average Asset Turnover Ratio	0.87	0.39	1.3
5yr Avg Net Profit Margin	2.4 %	20.95 %	9.23 %
Price to Book	4.98	1.03	7.68
P/E	0.0	0.0	30.41
5yr Avg Cash Conversion Cycle	61.25 Days	-83.17 Days	-46.65 Days
Inventory Days	70.72 Days	118.8 Days	63.59 Days
Days Receivable	84.11 Days	54.62 Days	23.17 Days
Days Payable	118.6 Days	284.35 Days	141.25 Days
5yr Average Interest Coverage Ratio	2.9	2.91	17.24
5yr Avg ROCE	9.0 %	-10.17 %	23.6 %
5yr Avg Operating Profit Margin	10.83 %	-2.87 %	17.39 %
5 yr average Debt to Equity	0.46	0.41	0.06
5yr CAGR Net Profit	n/a	n/a	44.3 %
5yr Average Return on Assets	1.98 %	7.46 %	11.89 %
Shareholdings
Promoter Holding	52.79 %	73.59 %	72.81 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-1.07 %	0.0	0.74 %
Change in Mutual Fund Holding (3 Yrs)	2.48 %	-1.27 %	1.47 %

Business

	Sequent Scientific	Panacea Biotec	RPG Life Sciences
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Segment Break-Up	Segment Break-Up Production animal 81.0 Companion animal 19.0 Both 0	-	-
Product Wise Break-Up	Product Wise Break-Up Formulations 77.4 Active Pharmaceutical Ingredient (API) 21.28 Research and Development 0 Vaccines 0 0 International Formulations 0 Domestic Formulations 0 Others 1.32	Product Wise Break-Up 0 Formulations 36.72 Domestic Formulations 0 International Formulations 0 Vaccines 63.28 Active Pharmaceutical Ingredient (API) 0 Research and Development 0	Product Wise Break-Up Active Pharmaceutical Ingredient (API) 15.0 Formulations 0 Domestic Formulations 66.0 International formulations 19.0 Vaccines 0 Active Pharmaceutical Ingredient (API) 0 Research and Development 0
Location Wise Break-Up	Location Wise Break-Up Europe 40.5 Asia Pacific 33.53 Rest of the World 25.97 Turkey 0 LATAM 0 EM 0 India 0	Location Wise Break-Up Europe 0 Turkey 0 EM 0 LATAM 0 India 24.12 Asia Pacific 0 Rest of the World 75.88	Location Wise Break-Up Europe 0 Turkey 0 EM 0 LATAM 0 India 68.38 Asia Pacific 0 Rest of the World 31.62
Customer Segment	Customer Segment Regulated market 72.0 Less regulated market 28.0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Antibiotic Injectables 33.0 Antibiotic Non-Injectables 15.0 Anthelmintics 11.0 Nutritional 0 Pain management 0 urology 0 oncology 0 respiratory 0 neuro 0 Gastro intestinal 0 Orthopedics 0 Nephrology 0 Cardio 0 Others 41.0	-	Therapeutic Area Break-Up Anthelmintics 0 oncology 0 Antibiotic Non-Injectables 0 Gastro intestinal 0 Orthopedics 0 Pain management 0 Nephrology 0 Antibiotic Injectables 0 respiratory 0 Cardio 0 urology 0 neuro 0 Nutritional 0 Others 100
R&D Break-Up - Product Wise	R&D Break-Up - Product Wise Formulations 40.0 NiCad 29.0 Patent expiry opportunity 18.0 First generic 9.0 Incremental innovation 4.0	-	-
Dosage Form Break-Up	Dosage Form Break-Up Injectable 55.0 Powder/Premixes 26.0 Solid 6.0 Paste and others 0 Pour on/Spot on 0 Oral Solutions/Suspensions 0 Others 13.0	-	-
Species Break-Up	Species Break-Up Multispecies 39.0 Ruminants 32.0 Poultry And Poultry Products 12.0 Companion 10.0 Swine 6.0 Others 1.0	-	-
Asset Break-Up	Asset Break-Up Asia Pacific 45.52 Europe 28.34 Rest of the World 26.15 Real Estate 0 Formulations 0 Vaccines 0	Asset Break-Up Real Estate 0 Europe 0 Formulations 35.15 Asia Pacific 0 Vaccines 64.85 Rest of the World 0	-

Sequent Scientific Ltd.

SIGN UP FOR FREE